

5th ANNUAL PCPA YEAR IN REVIEW

2021 Edition

*A high-level summary of the 2021
pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes*

pCPA ACTIVITY



Initiated 80 files
(2020: 53 files)



Completed 61 files
(2020: 49 files)



Closed 8 files
(2020: 6 files)



Declined 7 files
(2020: 7 files)

There was a **51% increase in files initiated** and a **24% increase in files completed** by pCPA in 2021 compared to 2020.

pCPA BACKLOG

Files Under Consideration




The backlog of files under consideration that began in 2020 due to COVID-19 related impacts continued into 2021 reaching a **peak of 37 in August**.

However, the **pCPA initiated considerably more files in 2021** than 2020, leading to a drop in the backlog by the end of the year.

pCPA PROCESS

Average Time to Complete a pCPA Negotiation




The **average time to complete a pCPA negotiation** in 2021 was comparable to 2020, with a **longer time to initiation** and **shorter duration of negotiation**.

Oncology files represented the majority of files which successfully negotiated an LOI in 2021 (n=22).

Biosimilar files completed the pCPA process faster on average (average duration of negotiation: 95 calendar days vs. 158 calendar days for all files).

Completed Files by Type



For further insight into this year's Canadian reimbursement trends, [click here](#) to find out how to purchase the MORSE 2022 Canadian Reimbursement and Forecasting Timelines (CRaFT) Report.